Biogen Inc. (BIIB) Stock

Biogen Inc. trades at a P/E ratio of 12.46, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 8.44 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 6.24 indicates a premium valuation even accounting for growth.

With a beta of 0.15, Biogen Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.09 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Biogen Inc. achieves a profit margin of 15.10%, meaning it retains $15.10 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 28.10% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 9.19% and ROA at 5.43%, the company achieves moderate returns on invested capital.

Biogen Inc.'s revenue grew by 6.10% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 39.30% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Biogen Inc. has a market capitalization of $18.47B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 146.53M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.

Biogen Inc.'s book value per share is $115.90, while the current stock price is $130.86, resulting in a price-to-book (P/B) ratio of 1.13. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

37 analysts cover BIIB with 49% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $172.20 implies 31.6% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:5 Strong Buy, 13 Buy, 19 Hold, 00The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.